- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03281694
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nicotinic acetylcholine receptor (nAChR) agonists such as nicotine have been shown to enhance cognitive performance, especially functions in the attention domain. Efforts have been made to develop similar compounds as therapeutic agents for disorders such as schizophrenia or Alzheimer's disease. Over the last two decades, drug development has invested into novel nAChR agonists. Effects have generally been in the expected direction, but tended to be of small magnitude. A potential way of increasing the effect size ceiling is by co-administering a nAChR positive allosteric modulator (PAM). PAMs generally do not activate the nAChR on their own but bind to a second, modulatory site and facilitate agonist-induced responses. The present study is aimed at testing the effects of AVL-3288, a PAM selective for the α7 nAChR subtype that is thought to be of particular relevance for cognition in schizophrenia, on cognitive task performance, and on nicotine-induced improvements in cognitive task performance, in healthy adult non-smokers.
The aim of the present study is to provide the proof-of-principle that the attention-enhancing effects of the prototypical nAChR agonist nicotine can be potentiated by an α7 nAChR PAM (AVL-3288). Potentiation of nAChR agonist effects by PAMs have been shown in preclinical behavioral assays. The availability of AVL-3288 as a safe pure nAChR PAM for human research allows testing the hypothesis that nicotine and AVL-3288 will have additive or synergistic effects, such that the attention-enhancing effects of nicotine and AVL-3288 combined will be greater than the effects of either drug alone.
AVL-3288 has shown preclinical efficacy in rat paradigms of attention and memory, including models of cognitive dysfunction1-3. A human study in healthy adults reported no adverse effects associated with AVL-3288, tested at doses of 3, 10, and 30 mg. Some of the participants tested with 3 mg were smokers, some on nicotine replacement.
The present study will adopt a repeated measures design, in which a single group of 24 healthy non-smokers will complete 4 test sessions, in each of which they perform the same three cognitive paradigms. In each session, a skin patch will be administered 5 hrs prior to testing, and a solution (3 mL) will be administered by mouth 1 hr prior to testing. The skin patch is either a 7 mg/24 hrs nicotine patch or a placebo patch. The solution either contains AVL-3288 (3 mg) or is inactive diluent only. Over the 4 test sessions, each participant will be tested with Placebo + Placebo, Nicotine + Placebo, Placebo + AVL-3288, and Nicotine + AVL-3288, in a 2x2 factorial design. The sequence of test conditions will be only known to the statistician and pharmacist and counterbalanced across subjects.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 21-50 years.
- Male or female willing to use qualified methods of contraception for the study duration and up to 2 months after its end. Qualified methods are: intrauterine device, condoms, oral contraceptives, surgical sterilization of the subject or the partner at least one year in advance, or postmenopausal status of the female defined as at least two years without menstruation.
- No exposure to any nicotine-containing product in the last year.
- Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.
- Normal or corrected to normal vision (at least 20/80).
- Body weight 110-220 lbs.
Exclusion Criteria:
- Pregnant or breast-feeding.
- DSM Axis I mood, anxiety or psychotic disorder.
- Drug or alcohol abuse or dependence currently or in the last 2 years.
- Cardiovascular or cerebrovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, stroke, severe arrhythmias, or EKG abnormalities (see below).
- Uncontrolled hypertension (resting systolic BP >150 or diastolic >95 mm Hg).
- Hypotension (resting systolic BP below 90 or diastolic below 60).
- Significant kidney or liver impairment.
- Moderate to severe asthma.
- Type I diabetes.
- Gastrointestinal illness.
- Use of any prescription or over-the-counter medication except birth control or non-steroidal antiinflammatory drugs on an as-needed basis.
- History of or current neurological illnesses, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
- Learning disability, mental retardation, or any other condition that impedes cognition.
- Any surgeries requiring full anesthesia scheduled within 2 weeks of any of the study test sessions.
- Inability to perform the Rapid Visual Information Processing Task.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Nicotine - AVL-3288 Interaction Study
Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
|
placebo skin patch and placebo oral solution
nicotine skin patch (7 mg/24 hrs) and placebo oral solution
placebo skin patch and AVL-3288 oral solution (3 mg)
nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spatial Attentional Resource Allocation Task reaction time
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
average reaction time of trials with a signal detection response
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Spatial Attentional Resource Allocation Task omission errors
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
percentage of trials on which no response was registered
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Rapid Visual Information Processing Task signal detection
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
signal detection index based on hit rate and false alarm rate
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Rapid Visual Information Processing Task reaction time
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
average reaction time on trials with a correct response
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Change Detection Task accuracy
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
% of correct responses
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Change Detection reaction time
Time Frame: 5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
average reaction time across trials
|
5 hrs after patch application (=1 hr after ingestion of oral solution) on each test day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vital signs: blood pressure
Time Frame: hourly for 8 hours on each test day
|
mm Hg
|
hourly for 8 hours on each test day
|
Vital signs: heart rate
Time Frame: hourly for 8 hours on each test day
|
beats per minute
|
hourly for 8 hours on each test day
|
ECG
Time Frame: Before and 4 hours after ingestion of oral solution on each test day
|
QTc interval
|
Before and 4 hours after ingestion of oral solution on each test day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-0009999
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Change
-
University Ramon LlullAinhoa Nieto Guisado; Mònica Solana-TramuntUnknownCognitive Change | Proprioception Change | Balance ChangeSpain
-
Applied Science & Performance InstituteActive, not recruitingCognitive Change | Mood Change | Mental ProcessesUnited States
-
National Council of Scientific and Technical Research...CompletedSleep | Cognitive Change | Mood Change | CreativityArgentina
-
Wake Forest UniversityNot yet recruiting
-
Biruni UniversityCompletedCognitive ChangeTurkey
-
University of MemphisCalerie LLCCompletedCognitive ChangeUnited States
-
Oregon Health and Science UniversityCompleted
-
University of MiamiUnited States Department of DefenseCompleted
-
Northumbria UniversityPerfetti van Melle SPACompletedCognitive ChangeUnited Kingdom
-
Universidad de GranadaCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States